key: cord-0979047-zi5zmixo
authors: Benkeser, David; Díaz, Iván; Luedtke, Alex; Segal, Jodi; Scharfstein, Daniel; Rosenblum, Michael
title: Improving precision and power in randomized trials for COVID‐19 treatments using covariate adjustment, for binary, ordinal, and time‐to‐event outcomes
date: 2020-09-26
journal: Biometrics
DOI: 10.1111/biom.13377
sha: 39c7caf2ca2936a3064b2f9173db8d940e07addc
doc_id: 979047
cord_uid: zi5zmixo

Time is of the essence in evaluating potential drugs and biologics for the treatment and prevention of COVID‐19. There are currently 876 randomized clinical trials (phase 2 and 3) of treatments for COVID‐19 registered on clinicaltrials.gov. Covariate adjustment is a statistical analysis method with potential to improve precision and reduce the required sample size for a substantial number of these trials. Though covariate adjustment is recommended by the U.S. Food and Drug Administration and the European Medicines Agency, it is underutilized, especially for the types of outcomes (binary, ordinal and time‐to‐event) that are common in COVID‐19 trials. To demonstrate the potential value added by covariate adjustment in this context, we simulated two‐arm, randomized trials comparing a hypothetical COVID‐19 treatment versus standard of care, where the primary outcome is binary, ordinal, or time‐to‐event. Our simulated distributions are derived from two sources: longitudinal data on over 500 patients hospitalized at Weill Cornell Medicine New York Presbyterian Hospital, and a Centers for Disease Control and Prevention (CDC) preliminary description of 2449 cases. In simulated trials with sample sizes ranging from 100 to 1000 participants, we found substantial precision gains from using covariate adjustment–equivalent to 4–18% reductions in the required sample size to achieve a desired power. This was the case for a variety of estimands (targets of inference). From these simulations, we conclude that covariate adjustment is a low‐risk, high‐reward approach to streamlining COVID‐19 treatment trials. We provide an R package and practical recommendations for implementation. This article is protected by copyright. All rights reserved

This paper builds on our report (Benkeser et al., 2020) written in response to a request by the U.S. Food and Drug Administration (FDA) for statistical analysis recommendations for COVID-19 treatment trials. We aim to help inform the choice of estimand (i.e., target of inference) and analysis method to be used in COVID-19 treatment trials. To this end, we describe treatment effect estimands for binary, ordinal and time-to-event outcomes.

Importantly, the interpretability of these estimands does not rely on correct specification of models. For binary outcomes, we consider the risk difference, relative risk, and odds ratio.

For ordinal outcomes, we consider the difference in means, the Mann-Whitney (rank-based) estimand, and the average of the cumulative log odds ratios over levels of the outcome. For time-to-event outcomes, we consider the difference in restricted mean survival times, the difference in survival probabilities, and the ratio of survival probabilities.

For each estimand, we give covariate adjusted estimators of these quantities that (1) leverage information from baseline variables and (2) are robust to model misspecification.

We introduce a new covariate adjustment method for ordinal outcomes, but use existing methods for binary and time-to-event outcomes. By incorporating baseline variable information, covariate adjusted estimators often enjoy smaller variance compared to estimators that ignore this information, thereby resulting in reductions in the required sample size to achieve a desired power.

To evaluate the performance of covariate adjusted estimators, we simulated two-arm, randomized trials comparing a hypothetical COVID-19 treatment versus standard of care.

Our simulated distributions are derived from two sources: longitudinal data on over 500 patients hospitalized at Weill Cornell Medicine New York Presbyterian Hospital prior to March 28, 2020, and a preliminary description of 2449 cases reported to the CDC from February 12 to March 16, 2020. We focused on hospitalized, COVID-19 positive patients and specified distributions for binary, ordinal and time-to-event outcomes based on information collected on intensive care unit (ICU) admission, intubation with ventilation, and death.

We conducted simulations using all three estimands when the outcome is ordinal, but only evaluated the risk difference when the outcome is binary and the restricted mean survival time and risk difference when the outcome is time-to-event.

After our aforementioned report (which contains some of our simulation results for ordinal and time-to-event outcomes), the FDA released a guidance for industry on COVID-19 treatment and prevention trials (FDA, 2020) . The guidance contains the following statement, which is similar to our key recommendation regarding covariate adjustment: "To improve the precision of treatment effect estimation and inference, sponsors should consider adjusting for prespecified prognostic baseline covariates (e.g., age, baseline severity, comorbidities) in the primary efficacy analysis and should propose methods of covariate adjustment."

There is already an extensive literature on the theory and practice of covariate adjustment, e.g., Yang and Tsiatis (2001) However, covariate adjustment is underutilized, particularly for trials with a binary, ordinal, or time-to-event outcome. Since many COVID-19 treatment trials focus on these types of outcomes, our goal is to demonstrate the potential benefits of covariate adjustment in these contexts. Recent examples of COVID-19 treatment trials include a trial of dexamethasone with 28-day mortality as the primary outcome (The RECOVERY Collaborative Group, 2020) and three trials of remdesivir with the following primary outcomes: clinical status on day 14 using a 7-point ordinal scale (Goldman et al., 2020) , time to clinical improvement (Wang et al., 2020) , and time to death (Beigel et al., 2020) .

The remainder of this paper is organized as follows. A brief background on covariate adjustment in randomized trials is provided in Section 2. Section 3 describes estimands is the sample proportion of bad outcomes among patients assigned to arm A = a. A covariate adjusted estimator of this quantity can be based on the standardization approach of Ge et al. (2011) , as indicated in the FDA COVID-19 guidance (FDA, 2020) . This estimator is identical to that of Moore and van der Laan (2009a) and for the risk difference it is a special case of estimators from Scharfstein et al. (1999) . First, a logistic regression model is fit for the probability of bad outcome given study arm and baseline variables. Next, for each participant (from both arms), a predicted probability of bad outcome is obtained under each possible arm assignment a ∈ {0, 1} by plugging in the participant's baseline variables and setting arm assignment A = 0 and A = 1, respectively, in the logistic regression model fit. Lastly, the covariate adjusted estimator of P (Y = 0 | A = a) is the sample mean over all participants (pooling across arms) of the predicted outcome setting A = a.

We consider three estimands when the outcome is ordinal, with levels 1, . . . , K. Without loss of generality, we assume that higher values of the ordinal outcome are preferable. In what follows we let (A, Y ) and ( A, Y ) denote independent treatment-outcome pairs.

Estimand 1: Difference in means (DIM). For u(·) a pre-specified, real-valued transformation of an outcome, the estimand is defined as:

In most settings, this transformation will be monotone increasing so that larger values of the ordinal outcome will result in larger, and therefore preferable, transformed outcomes.

Transformations could incorporate, e.g., utilities assigned to each level, as has been done in some stroke trials (Chaisinanunkul et al., 2015; Nogueira et al., 2018) .

Estimand 2: Mann-Whitney (MW) estimand. This estimand reports the probability that a random individual assigned to treatment will have a better outcome than a random individual assigned to control, with ties broken at random. The estimand is defined as:

Estimand 3: Log-odds ratio (LOR). We consider a nonparametric extension of the log-odds ratio (LOR) (Díaz et al., 2016) defined as the average of the cumulative log odds ratios over levels 1 to K − 1 of the outcome, namely LOR:

In the case that the distribution of the outcome given study arm is accurately described by a proportional odds model of the outcome against treatment (McCullagh, 1980) , this estimand is equal to the coefficient associated with treatment.

All three estimands are smooth summaries of the treatment-specific cumulative distribution functions (CDFs) of the ordinal outcome. The CDF for arm a ∈ {0, 1} evaluated

, and the corresponding probability mass function is denoted by f (j | a) = F (j | a) − F (j − 1 | a). The estimands can be equivalently expressed in terms of the CDFs as follows:

To estimate these quantities, it suffices to estimate the arm-specific CDFs and then to evaluate the summaries; such estimators are called plug-in estimators.

The unadjusted estimator of the CDF in each arm is the empirical distribution in that arm. The resulting plug-in estimator for the DIM is the difference between arms of sample means of the transformed outcomes. Also, the resulting plug-in estimator (denoted M ) for the MW estimand is closely related to the usual Mann-Whitney U-statistic U = n 0 n 1 M , where n 0 and n 1 are the total sample sizes in the two study arms.

Model-robust, covariate adjusted estimators are available for estimation of the MW estimand, e.g., Vermeulen et al. (2015) , and for the LOR estimand, e.g., Díaz et al. (2016) .

We use a slightly different approach as described below. It is an area of future research to compare the performance of our method to the those from related works.

Our covariate adjusted estimator of the CDF in each arm, presented in Appendix B of the Supporting Information, leverages prognostic information in baseline variables. It uses working models, i.e., models that are fit in the process of computing the estimator but which we do not assume to be correctly specified. Specifically, the adjusted estimator of the CDF for each study arm a ∈ {0, 1} is based on the following arm-specific, proportional odds working model for the cumulative probability of the outcome given the baseline variables: logit {P (Y j|A = a, X)} = α j + β X, for each j = 1, . . . , K − 1 with parameters α 1 , . . . , α K−1 and β; the model for the other study arm is the same but with a separate set of parameters. Each model is fit using data from the corresponding study arm, yielding two working covariate-conditional CDFs (one per arm). For each arm, the estimated marginal CDF is then obtained by averaging the corresponding conditional CDF across the empirical distribution of baseline covariates pooled across the two study arms. The above methods are implemented in an accompanying R package, drord.

The validity (i.e., consistency and asymptotic normality) of the adjusted CDF estimator given above in no way relies on correct specification of the aforementioned working model.

This property also holds for the estimators of Vermeulen et al. (2015) and Díaz et al. (2016) .

We consider three treatment effect estimands in the time-to-event setting, all of which are interpretable under violations of a proportional hazards assumption. To define these

This article is protected by copyright. All rights reserved. 8 estimands, we let T be a time-to-event outcome, C be a right-censoring time, A be a treatment indicator, and X be a collection of baseline covariates.

Estimand 1: Difference in restricted mean survival times (RMSTs). The RMST is the expected value of a survival time that is truncated at a specified time τ (Chen and Tsiatis, 2001; Royston and Parmar, 2011) , that is,

Estimand 2: Survival probability difference (also called risk difference, RD).

Difference between arm-specific probabilities of survival to a specified time t * , that is,

Estimand 3: Relative risk (RR). Ratio of the arm-specific probabilities of survival to a specified time t * , that is,

Analogous to the ordinal outcome case, estimators of these parameters can be constructed from estimators of the survival functions for each arm. One approach to constructing adjusted estimators, used here, involves discretizing time and then: (i) estimating the time-specific hazard conditional on baseline variables, (ii) transforming to survival probabilities using the product-limit formula, and (iii) marginalizing using the estimated covariate distribution (pooled across arms). The adjusted approach as implemented here (and elsewhere-see references below) has two key benefits relative to unadjusted alternatives such as using the unadjusted Kaplan-Meier estimator (Kaplan and Meier, 1958) . First, the adjusted estimator's consistency depends on an assumption of censoring being independent of the outcome given study arm and baseline covariates (C ⊥ ⊥ T | A, X), rather than an assumption of censoring in each arm being independent of the outcome marginally (C ⊥ ⊥ T | A). The former may be a more plausible assumption. Second, in large samples and under regularity conditions, the adjusted estimator is at least as precise as the unadjusted estimator in the case that censoring is completely at random, i.e., that in each arm a ∈ {0, 1}, C ⊥ ⊥ (T, X)|A = a.

Covariate adjusted estimators for time-to-event outcomes include, e.g., Chen and Tsiatis (2001) ; Rubin and van der Laan (2008b); Moore and van der Laan (2009b); Stitelman et al. 

In each setting below, we simulated trials with 1:1 randomization to the two arms and total enrollment of n = 100, 200, 500, and 1000. In each case, 1000 trials were simulated. In each simulated trial, the n participant data vectors are i.i.d. draws from a population data generating distribution that depends on the setting.

Data for simulated control-arm participants were simulated based on real data, while data for simulated treatment-arm participants were simulated by modifying the outcome distribution observed in the real data to achieve a desired level of treatment effect (details below). In all simulation settings, covariates are approximately, equally prognostic across arms and there is no treatment effect heterogeneity. lower and upper estimates were reported for each age group-specific outcome probability; we used the average of these within each age group to define our data generating distributions.

For the hospitalized COVID-19 positive population, the resulting outcome probabilities for each age group are listed in Table 1 .

[ Table 1 about here.]

We separately considered two types of treatment effects in our data generating distributions: no treatment effect and an effective treatment. For the former, we randomly sampled n age-outcome pairs according to the distribution in Table 1 and then independently assigned study arm with probability 1/2 for each arm.

For the latter case (effective treatment), we randomly generated control arm participants as in the previous paragraph and randomly generated treatment arm participants by modifying the values in Table 1 to achieve a desired level of true treatment effect. Specifically, the probabilities P(ICU admission and survived | age) in column 4 were proportionally reduced, while P(No ICU admission and survived | age) were increased by an equal amount.

The probabilities of death given age in column 3 were not changed. This modified table corresponds to a scenario where the treatment has no effect on the probability of death but decreases the odds of ICU admission among those who survive by the same relative amount in each age category.

The aforementioned relative reduction (and the resulting treatment effect) was separately selected for each sample size n = 100, 200, 500, 1000. For the DIM estimand at each sample size, we selected treatment effect sizes such that a t-test using the unadjusted estimator would achieve roughly 50% and 80% power, respectively, to reject the null hypothesis of no treatment effect. For sample size n = 100, we instead set this relative reduction to achieve roughly 30% and 40% power, respectively, because there did not exist a relative reduction that achieved 80% power at this sample size. The same data generating distributions used for the DIM estimand were also used for the MW and LOR estimands.

In our simulations, we used the adjusted estimator described in Section 3.2, where age is coded using the categories in Table 1 . Specifically, these age categories are included as the main terms in the linear parts of the proportional odds working models.

For simplicity, for binary and ordinal outcomes we simulated trials with no missing data.

However, the methods we used can adjust for missing outcomes. (See Appendix B of the Supporting Information.) 4.1.3 Time-to-event outcomes. In this simulation, the outcome is time from hospitalization to the first of intubation or death, and the predictive variables used are sex, age, whether the patient required supplemental oxygen at ED presentation, dyspnea, hypertension, and the presence of bilateral infiltrates on the chest x-ray. We focus on RMST 14 days after hospitalization, and the RD of remaining intubation-free and alive 7 days after hospitalization.

Our data generation distribution is based on a database of over 500 patients hospitalized at

Weill Cornell Medicine New York Presbyterian Hospital prior to March 28, 2020. Outcome information was known for all patients through at least day 14. Patient data were re-sampled with replacement to generate 1000 datasets, each of the sizes n = 100, 200, 500, and 1000. For each dataset, a hypothetical treatment variable was drawn from a Bernoulli distribution with probability 0.5 independently of all other variables. Positive treatment effects were simulated by adding an independent random draw from a χ 2 distribution to each participant's outcome in the treatment arm; we used χ 2 distributions with 2 and 4 degrees of freedom, respectively, to generate two different effect sizes. These data generating distributions correspond to a difference in RMST of 0.507 and 1.004 at 14 days, and an RD of 3.5% and 8.8% at seven days, respectively. Five percent of the patients were selected at random to be censored, and their censoring time was drawn from a uniform distribution on {1, . . . , 14}.

We compare the performance of the unadjusted, Kaplan-Meier-based estimator to the covariate adjusted estimator. These estimators are defined in Sections 4 and 6 of (Díaz et al., 2019) , respectively, and implemented in the R package survtmlerct. Wald-type confidence intervals and corresponding tests of the null hypothesis of no effect are reported.

We compare the type I error and power of tests of the null hypothesis H 0 of no treatment effect based on unadjusted and adjusted estimators, both within and across estimands. For each estimand, we also compare the bias, variance, and mean squared error of the unadjusted and the adjusted estimators.

We approximate the relative efficiency of the unadjusted relative to the adjusted estimator by the ratio of the mean squared error of the latter to the mean squared error of the former. In all of our simulation studies, this is similar to the corresponding ratio of variances, since the bias squared was always much smaller than the variance. One minus this relative efficiency is approximately the proportion reduction in sample size needed for a covariate adjusted estimator to achieve the same power as the unadjusted estimator (van der Vaart, 1998, pp.

110-111).

For binary and ordinal outcomes, we present results that use the nonparametric BCa bootstrap (Efron and Tibshirani, 1994) for confidence intervals and hypothesis tests. We used 1000

replicates for each BCa bootstrap confidence interval. While we recommend 10000 replicates in practice, the associated computational time was too demanding for our simulation study.

Nonetheless, we expect similar or slightly better performance with an increased number of bootstrap samples. Results that use closed-form, Wald-based inference methods are presented in Appendix C of the Supporting Information.

For time-to-event outcomes, we used Wald-based confidence intervals since these made the computations faster compared to the BCa bootstrap method. Table 2 compares the performance of the unadjusted and adjusted estimators when the outcome is death or survival with ICU admission, and the estimand is the risk difference.

The relative efficiency of unadjusted method relative to the adjusted method varied from 0.92 to 0.86. This is roughly equivalent to needing 8-14% smaller sample size when using the adjusted estimator compared to the unadjusted estimator, to achieve the same power.

Type I error of the covariate adjusted method was comparable to that of the unadjusted method. The covariate adjusted method achieved higher power across all settings. Absolute gains in power varied from 5% to 14%.

[ (DIM), 6-15% (MW), and 7-15% (LOR) smaller sample sizes, respectively, when using the adjusted estimator compared to the unadjusted estimator, to achieve the same power.

Type I error control of the covariate adjusted methods was comparable to that of the unadjusted methods. The covariate adjusted methods achieved higher power across all settings.

Absolute gains in power varied from 1% to 6% for the DIM, 1% to 6% for the MW estimand, and 1% to 5% for the LOR.

[ To evaluate the importance of adjusting for multiple baseline variables, we also evaluated an adjusted RMST estimator that only adjusts for age and sex; see Appendix C of the Supporting Information. The gains of the covariate adjusted methods relative to the unadjusted methods were small, with absolute gains in power of approximately 0%-1% and relative efficiency ranging from 0.96 to 1.00. These results suggest that there can be a meaningful benefit from adjusting for prognostic covariates beyond just age and sex.

We also considered the risk difference (RD) estimand; see Appendix C of the Supporting Information. The results (when adjusting for age and sex along with the four other variables described in Section 4.1.3) are qualitatively similar, except with slightly smaller precision gains, to those for the RMST in Table 6 .

The Type I error in Table 6 for the unadjusted estimator at n = 100 is 1.1%, much smaller than the nominal level. We conjecture this is due to the Wald-type asymptotic inference procedure being a poor approximation at this sample size. This is illustrated by the fact that the scaled variance at n = 100 is much smaller than the scaled variance at n = 1000.

Similar comments apply to some of the results in Appendix C of the Supporting Information.

[ Table 6 about here.]

Recommendations below that do not reference related work or our simulation results are based on the authors' experience.

(1) Estimand when the outcome is ordinal. If a utility function can be agreed upon to transform the outcome to a score with a clinically meaningful scale, then we recommend using the difference between the transformed means in the treatment and control arms.

Otherwise, we recommend using the unweighted difference between means or the Mann-Whitney estimand. We recommend against estimating log odds ratios, since clinical interpretation requires considerable nuance (Díaz et al., 2016) and the corresponding estimators (even unadjusted ones) can be unstable at small sample sizes (Appendix C of the Supporting Information).

(2) Covariate adjustment. Based on our simulations, we recommend adjustment for prognostic baseline variables to improve precision and power. In the context of COVID-19 trials, we expect improvements to be substantial since there are already several known prognostic baseline variables, e.g., age and co-morbidities. We did not consider it here, but one may consider using an algorithm for variable selection from a prespecified list of candidate variables; see, e.g., Tsiatis et al. (2008) (4) Information monitoring. We summarize our recommendations below and give more detailed recommendations in Appendix E of the Supporting Information. First, consider trials without interim analyses. Information monitoring can be used to determine how long the trial will continue. Before starting the trial, one computes the information level required to achieve the desired power at a fixed alternative. Then during the trial, the accrued information (defined as the reciprocal of the estimator's variance) is monitored and the trial is continued until the required information level is surpassed. In this way, covariate adjustment can lead to faster trials even when the treatment effect is zero (i.e., when the null hypothesis is true); this may be more ethical in settings where it is desirable to stop as early as possible to avoid unnecessary exposure to side effects.

Next, consider trials with interim analyses. For the estimands and adjusted estimators that we considered for continuous, binary, or ordinal outcomes, one can directly apply the group sequential, information-based designs of Scharfstein et al. (1997) ; Turnbull (1997, 1999) . This can be done as long as data from pipeline participants, that is, participants who enrolled but have not been in the study long enough to have their primary outcomes measured, are not used when conducting interim analyses.

This is because the key property needed to apply the aforementioned group sequential designs, called the independent-increments property, is only guaranteed to hold if pipeline participant information is not used. There are methods for modifying the estimators through orthogonalization so that the independent increments property holds even when using pipepline participant information (and similarly when the outcome is time-toevent), but this was not simulated in our paper and is an area of future research.

(5) Plotting the CDF and the probability mass function (PMF) when the outcome is ordinal. Regardless of which treatment effect definition is used in the primary efficacy analysis, we recommend that the covariate adjusted estimate of the PMF and/or CDF of the primary outcome be plotted for each study arm when the outcome is ordinal.

Pointwise and simultaneous confidence intervals should be displayed (where the latter account for multiple comparisons). This is analogous to plotting Kaplan-Meier curves for time-to-event outcomes, which can help in interpreting the trial results. For example, Figure 1 shows covariate adjusted estimates of the CDF and PMF for a data set from our simulation study. From the plots, it is evident that the effect of the treatment on the ordinal outcome is primarily through preventing ICU admission, with no impact on probability of death.

(6) Missing covariates. We do not recommend adjusting for baseline covariates that are expected to have high levels of missing data. For the situation with low levels of missing data, it is simplest to singly impute missing values based only on data from those baseline covariates that were observed. To ensure that treatment assignment is independent of all baseline covariates (including imputed ones), no treatment or outcome information should be used in this imputation. For performing inference based on the bootstrap, the bootstrap sample should be drawn first, then missing covariates should be imputed.

(7) Missing ordinal outcomes. We recommend handling missing ordinal outcomes using methods that are robust to model misspecification, such as the one described in Appendix B of the Supporting Information. Compared to a complete-case analysis, these approaches weaken the assumption of missingness from missing completely at random to missing at random. Nevertheless, these methods are still subject to bias in the presence of unmeasured factors that influence the study outcome and missingness probability.

Therefore, trials should seek to minimize the likelihood of missing outcomes and employ relevant sensitivity analyses to address robustness of studying findings to assumptions about missing data (National Research Council, 2010) ; this applies to all outcome types.

(8) Loss to follow up with time-to-event outcomes. We recommend accounting for loss-to-follow-up using methods that are robust to model misspecification such as those described in Benkeser et al. (2018) ; Díaz et al. (2019) . These methods rely on a potentially more plausible condition on the censoring distribution than do unadjusted methods, as discussed in Section 3.3. The covariate adjusted estimator that we used for the restricted mean survival time in the time-to-event setting is robust to misspecification of one of its working models (as long as the other is correctly specified) under censoring being independent of the outcome given baseline variables and arm assignment.

In our simulated data generating distributions, the correlations between baseline variables and the outcome were similar for each arm. Because we designed our data generating distributions to mimic the correlations between baseline variables and outcomes from observational study data, these may be reasonable approximations to the control arm (i.e., standard of care) of a trial involving the same population. If the treatment arm in such a trial has similar correlations between baseline variables and the outcome, then the precision gains in such a trial may be similar to those in our simulations. However, if the treatment arm in such a trial has smaller correlations between baseline variables and the outcome, then the precision gains in such a trial may be smaller than those in our simulations.

Adjusting for baseline variables beyond just age and sex led to substantial improvements in precision in our simulations involving time-to-event outcomes, as described in Section 5.3.

For the other outcome types, i.e., binary and ordinal, our data generating distributions only had one baseline variable, age; this is all that was available in the CDC data, so we were not able to investigate the value added by adjusting for more variables.

The described methods for binary and ordinal outcomes can be adapted to handle the case where stratified randomization on a subset of the measured baseline covariates is used.

Specifically, one can apply the general method of Wang et al. (2019), which gives a formula for consistently estimating the asymptotic variance of covariate adjusted estimators under stratified randomization. This method can be applied to any M-estimator, and therefore applies to the estimators that we considered for binary and ordinal outcomes. To the best of our knowledge, it is an open problem to prove consistency and asymptotic normality for

This article is protected by copyright. All rights reserved. 

The data and code needed to reproduce the simulations for ordinal and binary outcomes are available on GitHub at https://github.com/mrosenblum/COVID-19-RCT-STAT-TOOLS.

These data were derived from the following resource available in the public domain: (CDC COVID-19 Response Team, 2020). The code for the survival simulations is also included in that repository. However, because the simulation is based on private data from Weill Cornell Medicine (research data not shared), the results of the survival simulation reported in the manuscript are not reproducible based on the available code. We provide a simulated dataset (not based on real data) with the same structure of the real dataset and that can be used to run the simulation code.

https://biostats.bepress.com/jhubiostat/paper285 . Zhang, M., Tsiatis, A. A., and Davidian, M. (2008) . Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics 64, 707-715.

The R package drord is available on Github at https://github.com/benkeser/drord, and the R package survtmlerct is available on Github at https://github.com/idiazst/survtmlerct. Figure 1 . Example figures illustrating covariate adjusted estimates of the PMF and CDF by study arm with pointwise (black) and simultaneous (gray) confidence intervals. "ICU" represents survival and ICU admission; "None" represents survival and no ICU admission. Table 2 Results for the binary outcome and risk difference (RD) estimand in the hospitalized population. BCa bootstrap is used for confidence intervals and hypothesis testing. "Effect" denotes the true estimand value; "MSE" denotes mean squared error; "Rel. Eff." denotes relative efficiency which we approximate as the ratio of the MSE of the estimator under consideration to the MSE of the unadjusted estimator. In each block of six rows, the first two rows involve no treatment effect and the last four rows involve a benefit from treatment. MSE and variance are scaled by n; bias is scaled by n 1/2 . Table 3 Results for the ordinal outcome and difference in means (DIM) estimand in the hospitalized population. BCa bootstrap is used for confidence intervals and hypothesis testing. "Effect" denotes the true estimand value; "MSE" denotes mean squared error; "Rel. Eff." denotes relative efficiency which we approximate as the ratio of the MSE of the estimator under consideration to the MSE of the unadjusted estimator. In each block of six rows, the first two rows involve no treatment effect and the last four rows involve a benefit from treatment. MSE and variance are scaled by n; bias is scaled by n 1/2 . Table 4 Results for ordinal outcome and Mann Whitney (MW) estimand in the hospitalized population. BCa bootstrap is used for confidence intervals and hypothesis testing. "Effect" denotes the true estimand value; "MSE" denotes mean squared error; "Rel. Eff." denotes relative efficiency which we approximate as the ratio of the MSE of the estimator under consideration to the MSE of the unadjusted estimator. In each block of six rows, the first two rows involve no treatment effect and the last four rows involve a benefit from treatment. MSE and variance are scaled by n; bias is scaled by n 1/2 . Table 5 Results for the ordinal outcome and log-odds ratio (LOR) estimand in the hospitalized population. BCa bootstrap is used for confidence intervals and hypothesis testing. "Effect" denotes the true estimand value; "MSE" denotes mean squared error; "Rel. Eff." denotes relative efficiency which we approximate as the ratio of the MSE of the estimator under consideration to the MSE of the unadjusted estimator. In each block of six rows, the first two rows involve no treatment effect and the last four rows involve a benefit from treatment. MSE and variance are scaled by n; bias is scaled by n 1/2 . 

A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Improved estimation of the cumulative incidence of rare outcomes

Improving Precision and Power in Randomized Trials for COVID-19

Treatments Using Covariate Adjustment, for Ordinal or Time to Event Outcomes

Estimating and testing vaccine sieve effects using machine learning

Lasso adjustments of treatment effect estimates in randomized experiments

Targeted minimum loss-based estimation of causal effects in right-censored survival data with time-dependent covariates: Warfarin, stroke, and death in atrial fibrillation

Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) -United States

Adopting a patient-centered approach to primary outcome analysis of acute stroke trials using a utility-weighted modified rankin scale

Causal inference on the difference of the restricted mean lifetime between two groups

Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards

Enhanced precision in the analysis of randomized trials with ordinal outcomes

An introduction to the bootstrap

Guideline on adjustment for baseline covariates in clinical trials. Reference number EMA/CHMP/295050/2013. Committee for Medicinal Products for Human Use

Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biologics with Continuous Outcomes. Draft Guidance for Industry

COVID-19: Developing Drugs and Biological Products for Treatment or Prevention. Guidance for Industry

E9 statistical principles for clinical trials. U.S. Food and Drug Administration: CDER/CBER

Covariate-adjusted difference in proportions from clinical trials using logistic regression and weighted risk differences

Remdesivir for 5 or 10 days in patients with severe covid-19

Group-sequential analysis incorporating covariate information

Group sequential methods with applications to clinical trials

Robust alternatives to ancova for estimating the treatment effect via a randomized comparative study

Nonparametric estimation from incomplete observations

Semiparametric estimation of treatment effect with timelagged response in the presence of informative censoring

Regression models for ordinal data

Robust extraction of covariate information to improve estimation efficiency in randomized trials

Covariate adjustment in randomized trials with binary outcomes: Targeted maximum likelihood estimation

Increasing power in randomized trials with right censored outcomes through covariate adjustment

The Prevention and Treatment of Missing Data in Clinical Trials

Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct

Landmark estimation of survival and treatment effect in a randomized clinical trial

Improving power in group sequential, randomized trials by adjusting for prognostic baseline variables and short-term outcomes

 Table 6 Results for difference in restricted mean survival times (RMST) at 14 days estimand in hospitalized population, when the adjusted estimator uses all six baseline variables from Section 4.1.3. Confidence intervals and hypothesis tests are Wald-based. "Effect" denotes the true estimand value; "MSE" denotes mean squared error; "Rel. Eff." denotes relative efficiency which we approximate as the ratio of the MSE of the estimator under consideration to the MSE of the unadjusted estimator. In each block of four rows, the first two rows involve no treatment effect and the last two rows involve a benefit from treatment. MSE and variance are scaled by n; bias is scaled by n 1/2 .